Jean-Paul St-Pierre

Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada.

Synapse Technologies Inc. develops an Alzheimer's diagnostic test and potential blood/brain drug delivery mechanism based on the p97 protein.

Sandoz Canada, Inc. develops, manufactures, and distributes injections and ophthalmic pharmaceutical products for the hospital and retail markets. It offers ampoules, vials ophthalmic solutions, suspensions and ointments, and suppositories. The company was founded in 1973 and is headquartered in Boucherville, Canada.